Ilan Oren
Independent ChairmanMr. Ilan Oren, B.A., is Independent Director of Roivant Sciences Ltd. since 2014 and serves as its Chairman since February 2023. He serves as the Chairman of the Board at Syremis Therapeutics Ltd. He has been the Co-Chief Executive Officer at Dexcel Ltd. since November 2019. He has been Director of Kriya Therapeutics, Inc. since May 2020. Mr. Oren served as Vice President of Business Development at Dexcel Ltd. (alternate name Dexcel Pharma Technologies Ltd.) since September 2011 until November 2019, where led corporate and business development activities, including formation of strategic ventures, product partnerships, product portfolio selection, product acquisitions, strategic investments and mergers and acquisitions. Mr. Oren was employed by L.E.K. Consulting, advising clients in the life science sector on corporate strategy, M&A, licensing and drug commercialization projects from September 2007 to July 2011. He had been a Director of Axovant Gene Therapies Ltd. (formerly known as Axovant Sciences Ltd.) since June 6, 2018 until September 24, 2020. He previously served as a Director of Axovant Gene Therapies Ltd. (formerly known as Axovant Sciences Ltd.) since March 2015 until December 2017. Mr. Oren served as an Independent Director of Cynapsus Therapeutics Inc. since May 9, 2013 until October 20, 2016. Mr. Oren holds a B.A. in Economics from Harvard College.
Positions
- Company NameRoivant Sciences Ltd.Stock CodeROIVPositionIndependent Chairman
